Myrexis, Inc. (MYRX) [Rocket]

Overview

Myrexis, Inc. (MYRX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
08/17/2021	4	Form 4 - Statement of changes in beneficial ownership of securities:
08/26/2020	4	COUCHMAN JONATHAN (10% Owner) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.
08/06/2020	4	COUCHMAN JONATHAN (10% Owner) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.
08/06/2020	3	COUCHMAN JONATHAN (10% Owner) has filed a Form 3 on ENZON PHARMACEUTICALS, INC.
03/31/2020	4/A	COUCHMAN JONATHAN (10% Owner) has filed a Form 4 on ENZON PHARMACEUTICALS, INC.
03/31/2020	3	Myrexis, Inc. (See Footnote 1) has filed a Form 3 on ENZON PHARMACEUTICALS, INC.
07/31/2013	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Jun-30-13	Jun-30-12	Jun-30-11	Jun-30-10	Jun-30-09	Jun-30-08	Jun-30-07
Revenues	0.0	0.0	0.2	0.1	5.5	110.8	11.8
Revenue growth		-100.0%	105.6%	-98.4%	-95.1%	835.5%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.2	0.1	5.5	110.8	11.8
Gross margin			100.0%	100.0%	100.0%	100.0%	100.0%
Selling, general and administrative						20.6	10.3
Research and development	0.5	14.2	22.3	28.2	54.6	121.5	94.9
General and administrative	11.5	17.6	18.3	20.0	9.0
EBITA	-12.0	-31.8	-40.5	-48.0	-58.1	-31.4	-93.3
EBITA margin			-21864.9%	-53356.7%	-1065.5%	-28.3%	-788.3%
Amortization of intangibles				0.1
EBIT	-12.0	-31.8	-40.5	-48.1	-58.1	-31.4	-93.3
EBIT margin			-21864.9%	-53462.2%	-1065.5%	-28.3%	-788.3%
Pre-tax income	-11.6	-31.2	-38.7	-47.0	-58.1	-34.4	-92.7
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-11.6	-31.2	-38.7	-47.0	-58.1	-34.4	-92.7
Net margin			-20923.2%	-52167.8%	-1065.5%	-31.0%	-782.7%

Diluted EPS	($0.39)	($1.18)	($1.52)	($1.91)	($2.43)
Shares outstanding (diluted)	29.5	26.4	25.5	24.5	23.9

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.